glp-1 nejm Fair Allocation of and Dual GLP-1–GIP Receptor Agonists Expanding Clinical Benefits for GLP-1–Receptor

SKU: 57700707965

Pay in 4 interest-free payments of $5.71 Learn more

Live Spec

Expanding Clinical Benefits for GLP 1Receptor Agonists NEJM Clinician New @NEJM review on GLP 1 receptor agonists just out: effects on glucose, weight, cardiovascular outcomes, #MASLD and kidney outcomes but important questions remain about durability, lean mass (muscle + bone) loss, and GLP 1 and the kidney: from physiology to pharmacology and outcomes in diabetes Nature Reviews Nephrology In the FLOW trial, researchers assessed whether the glucagon like peptide 1 receptor agonist semaglutide was effective in preventing progression of kidney disease in patients with type 2 diabetes and chronic kidney disease. GLP 1 Receptor Agonists New England Journal of Medicine NEJM Clinician Editor in Chief Raja Elie Abdulnour, MD, shares some key results of a recent analysis of a VA database on the relation between GLP 1s and pancreatitis. The New England Journal of

Store: www.ab-travaux.com · Domain: www.ab-travaux.com